Brandon J. Essink

Family Medicine

2301 Eastern Ave
Red Oak, IA 51566

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.

Journal: The New England journal of medicine

Published: April 08, 2026

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 30, 2026

Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.

Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.

Journal: Vaccine

Published: December 02, 2025

Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.

Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.

Journal: Human vaccines & immunotherapeutics

Published: September 15, 2025

Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.

Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.

Journal: Vaccine

Published: April 26, 2025

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial.

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial.

Journal: Communications medicine

Published: April 15, 2025

An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.

An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.

Journal: Human vaccines & immunotherapeutics

Published: April 02, 2025

Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.

Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.

Journal: The Lancet. Infectious diseases

Published: December 23, 2024

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.

Journal: Nature communications

Published: November 05, 2024

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.

Journal: Human vaccines & immunotherapeutics

Published: October 18, 2024

A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.

A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.

Journal: Vaccine

Published: September 16, 2024

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children.

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children.

Journal: Expert review of vaccines

Published: September 05, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026